Navigation Links
Curoverse Raises $1.5 Million to Build Open Source Platform for Genomic and Biomedical Big Data
Date:12/18/2013

al School. "The Arvados software and the data collected through Personal Genome Projects can be a foundation for the development and delivery of precision medicine in cancer, neo-natal care, inherited diseases, pharmacogenomics, and a variety of other applications."

The series seed financing round included investments from Hatteras Venture Partners, Point Judith Ventures, Common Angels, MassVentures, and Boston Global Ventures.

"For the last several years we have closely followed the market for bioinformatics platforms that address new challenges created by next-generation sequencing and biomedical big data," said Clay Thorp, general partner at Hatteras Venture Partners. "Curoverse has a clear strategy to use open source technology with a unique go-to-market model that is well-aligned with the needs of research and clinical customers."

Curoverse is available today through a private beta program. The company plans to release their first commercial products in 2014. The Arvados software is available at http://arvados.org.

About Curoverse

Curoverse is a venture-backed startup developing computational storage infrastructure for a new era of precision medicine driven by genomic and biomedical big data. Based in Boston, Curoverse is a major contributor to the Arvados free and open source software project. Curoverse was formerly known as Clinical Future, Inc. More information is available about the company at http://curoverse.com.

Press Contact
Jonathan Sheffi, Curoverse
(617) 448-9298
jonathan(at)curoverse(dot)com

Read the full story at http://www.prweb.com/releases/2013/12/prweb11424292.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. The Holistic Sanctuary Raises Alarm About Teenage Drug Addiction
2. Immune Design Raises Up to $49 Million Series C Financing
3. Acacia Pharma Raises £15 Million ($23.5 Million) to Advance Clinical Development of Lead Products for Supportive Care
4. Intrexon Corporation Raises $150 Million for Synthetic Biology Initiatives
5. Advanced Animal Diagnostics Raises $6 Million for On-farm Diagnostics
6. OriGene Technologies Raises $21.3 Million in Series C Funding
7. Z Trim Holdings Announces Conclusion of Successful Warrant Exercise Program: Raises $2.195 Million
8. Strand Raises Series B From Burrill & Company
9. Ian Somerhalder Raises Big Money for the Environment; Optimal Chemical Comments His Effort Proves He's a True Green Celebrity
10. MiMedx Group Announces Record Third Quarter Results And Raises Revenue Estimates For The Year
11. OxThera Raises Capital for Further Clinical Development of Oxabact(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ) ... optimized Erk inhibitor molecule for development, thus achieving ... new class of potential cancer therapies. ... for therapeutic intervention in cancer. Recently approved compounds ... B-Raf and Mek inhibitors. Erk inhibitors may be ...
(Date:7/29/2015)... ... July 29, 2015 , ... Available in ... Express Contouring Bi-Gel, a nighttime-specific product that targets fat cells for extreme contouring ... able to enter fat cells, inhibiting the formation of new fat. Upon waking ...
(Date:7/29/2015)... ... 29, 2015 , ... Asymmetrex, LLC founder and ... the full range of capabilities of its unique cache of technologies for identifying, ... day-to-day renewal and repair of normal tissues and organs. This property makes them ...
(Date:7/28/2015)... ... July 29, 2015 , ... Strong Animals™ announced today that research conducted ... and presented at the ADSA-ASAS Joint Annual Meeting held July 12-16 in Orlando, FL ... and increased milk fat content. Also, feed containing Stay Strong™ for Dairy Cows took ...
Breaking Biology Technology:Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4Strong Animals™ Announces South Dakota State University Research Demonstrates Stay Strong™ for Dairy Cows Improves Performance and Feed Stability 2
... WEST LAFAYETTE, Ind. - Researchers have developed a ... "biosensors," a tool that could help industry perfect ... to environmental monitoring. , The experimental devices represent ... capture and detect specific "target molecules," which will ...
... the Board ... Neill Named President, ISELIN, N.J., Jan. 3 Pharmos Corporation,(Nasdaq: ... effective immediately., Board Changes, Robert F. Johnston has been elected ... and Mony Ben Dor have retired from,the Board., The Pharmos Board ...
... Jan. 3 Danaher Corporation (NYSE:,DHR) announced that ... will be presenting at the J.P. Morgan Healthcare ... 11:00 a.m. EST. The audio will be,simultaneously webcast ... on http://www.danaher.com for one week., ...
Cached Biology Technology:Model is first to compare performance of 'biosensors' 2Model is first to compare performance of 'biosensors' 3Pharmos Corporation Announces Board and Management Changes 2Pharmos Corporation Announces Board and Management Changes 3
(Date:7/9/2015)... Calif. , July 9, 2015  Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... Thursday, July 30, 2015 after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. ... of human interface solutions, today announced a ... first fully hardware encapsulated fingerprint sensor and ... technology is literally off the grid, isolating ... matching within the fingerprint sensor to provide ...
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. (NASDAQ: ... diagnostics, today announced the launch of a study ... Precision Cancer Monitoring℠ (PCM) technology for predicting response ... or a combination of the novel immunotherapy agents ... a PD-1 inhibitor. The 50-patient study will be ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... fact that they eat a lot and often may ... majority of fungal pathogens, according to research from Albert Einstein College ... the Journal of Infectious Diseases , showed that the elevated ... C in people is too high for the vast majority ...
... 15, 2009 / b3c newswire / - KINAXO ... that they will enter into collaboration. KINAXO will ... identification of novel biomarkers in a clinical trial ... allows annotation and quantification of regulated phosphorylation sites. ...
... Testicular cancer survivors can face an increased risk ... the highly effective treatment they receive, according to a ... Researchers from the Norwegian Radium Hospital at ... problems faced by survivors are higher than generally thought, ...
Cached Biology News:Do 3 meals a day keep fungi away? 2KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 2KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 3KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 4Treatment not testicular cancer poses greatest risk to survivors' long-term health 2Treatment not testicular cancer poses greatest risk to survivors' long-term health 3
... DASGIP Overhead Drive for individual and parallel ... flexible agitation of DASGIP vessels, featuring range ... ,Up to 16 overhead drives can ... Cultivation Systems fedbatch-pro® and cellferm-pro® for microbiology ...
... Whatever your Ion Chromatography requirements, IonQuest ... The newly developed conductivity detector has ... drift . In addition to the ... used with other detectors, such as electrochemical, ...
This pump accomodates StemSep ; pump feed columns of the following sizes : 0.3in., 0.5in., 0.6in., and 1.0in.....
...
Biology Products: